Table I.

The percentage of cells in different phases of the cell cycle following ATO treatment in SK-MES-1 cells.

	Cell cycle phase distribution, %
ATO dose	Sub-G1	G1	S	G2/M
0 µM	9.9±4.6	55.1±4.0	14.2±2.1	20.9±2.8
1.25 µM	11.3±4.3	48.2±1.2a	16.6±3.6	23.9±2.0
2.5 µM	12.7±3.5	44.7±2.8a	15.5±5.6	27.1±0.9a
5 µM	10.6±5.3	36.4±1.1b	19.0±1.3	34.1±5.1a

^aP<0.05

^bP<0.01 compared with the control. ATO, arsenic trioxide.